David Ostransky, DO
Pulmonary Disease · Fort Worth, TXNPI 1396710984
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,682 of the $107,429 with a category attached, or 73.2%. 17 manufacturers reported payments, led by Boehringer Ingelheim at 42.7% of the total. Reporting peaked in 2019 at $36,466 and has fallen 64.7% since, to $12,883 in 2025. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 294 payments — averaging $365.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$46K
- AstraZeneca$24K
- Jazz Pharmaceuticals Inc.$23K
- Avadel CNS Pharmaceuticals, LLC$5K
- Inspire Medical Systems, Inc.$4K
- Genentech USA, Inc.$1K
- plus $4K from 11 others
Across 8 payments — averaging $3474.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca AB$12K
- AstraZeneca$8K
- Novartis$7K
- Boehringer Ingelheim$350
What the payments were for
- Consulting fees$12,33011%
- Speaking & faculty fees$78,68273%
- Grants$1,0001%
- Travel & lodging$6,8136%
- Food & beverage$8,2518%
- Education$3530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 59 | $45,924 |
| AstraZeneca | 60 | $24,084 |
| Jazz Pharmaceuticals Inc. | 48 | $23,443 |
| Avadel CNS Pharmaceuticals, LLC | 9 | $5,058 |
| Inspire Medical Systems, Inc. | 22 | $3,601 |
| Genentech USA, Inc. | 1 | $1,455 |
| Novartis | 1 | $1,330 |
| Genentech, Inc. | 1 | $1,000 |
| GSK | 67 | $819 |
| Advanced Respiratory, Inc | 14 | $170 |
| ZOLL Respicardia, Inc. | 2 | $166 |
| Insmed, Inc. | 1 | $130 |
| Harmony Biosciences LLC | 4 | $90 |
| Pulmonx Corporation | 1 | $81 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Verona Pharma, Inc. | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$22,424
- XYWAV$22,002
- LUMRYZ$4,870
- Inspire$2,761
- XOLAIR$1,455
- STIOLTO RESPIMAT$1,420
- Inspire Upper Airway Stimulation System$370
- TEZSPIRE$346
- FASENRA$294
- NUCALA$232
- AIRSUPRA$122
- SUNOSI$112
- remede System$111
How this compares
$107,429 in reported general payments places this provider in the 95th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 683 | $558,432 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 306 | $264,884 |
| XyremSodium Oxybate | 12 | $236,864 |
| NucalaMepolizumab | 35 | $136,811 |
| Spiriva RespimatTiotropium Bromide | 169 | $131,754 |
| Fasenra PenBenralizumab | 23 | $128,860 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 188 | $117,414 |
| OfevNintedanib Esylate | 14 | $110,562 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 147 | $88,844 |
| XolairOmalizumab | 17 | $63,468 |
| SymbicortBudesonide/Formoterol Fumarate | 184 | $56,869 |
| Dupixent SyringeDupilumab | 13 | $43,935 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 225 | $34,298 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 52 | $32,059 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $31,297 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $819 | $840,538980 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Ofev, Combivent Respimat | $45,924 | $391,789423 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Pulmicort Flexhaler | $24,084 | $324,145502 claims |
| Genentech, Inc.Xolair | $1,000 | $63,46817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Fort Worth
- Steven KimFort Worth$160K
- Andrew MillerFort Worth$112K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.